Minocycline topical- BioPharmX Corporation

Drug Profile

Minocycline topical- BioPharmX Corporation

Alternative Names: BPX-01; BPX-04

Latest Information Update: 02 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioPharmX Corporation
  • Class Amides; Anti-inflammatories; Antiacnes; Antibacterials; Dimethylamines; Neuroprotectants; Skin disorder therapies; Small molecules; Tetracyclines
  • Mechanism of Action Glial cell inhibitors; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acne vulgaris; Rosacea

Most Recent Events

  • 31 Jul 2018 BioPharmX receives approval from the Institutional Review Board (IRB) to initiate phase II trial of BPX 04 in Rosacea
  • 19 Jul 2018 The US FDA waives off its requirement for a dermal carcinogenicity study for BPX 01
  • 19 Jul 2018 Minocycline topical- BioPharmX Corporation is available for licensing as of 26 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top